Back to search
FDAFDA · Food and drugs·Recall number D-1106-2023

NAD+ 200mg/ml, 10ml vials, Tailor Made Compounding.

Published August 30, 2023 · Recall initiated: August 15, 2023

Summary

FDA records drug Class II recall D-1106-2023, published August 30, 2023 and initiated August 15, 2023. Recalling firm: TMC Acquisitions LLC dba Tailor Made Compounding; Status: Terminated; Reported quantity: 99 vials; Lot: Lot#: 07192307A2, BUD: 11/18/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
TMC Acquisitions LLC dba Tailor Made Compounding
Distributor
Nationwide within the USA
Lot
Lot#: 07192307A2, BUD: 11/18/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was NAD+ 200mg/ml, 10ml vials, Tailor Made Compounding. recalled?

Yes. FDA published recall D-1106-2023 on August 30, 2023. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter